# JUPITER-06

Source: https://onco.cc/trials/jupiter-06/  
OnCo record `jupiter-06` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The trial that added toripalimab to chemotherapy for oesophageal cancer in China and showed a survival gain regardless of PD-L1 level.

## Summary

514 patients. Median overall survival 17.0 versus 11.0 months (hazard ratio 0.58) and progression-free survival 5.7 versus 5.5 months (hazard ratio 0.58) at the interim analysis, with benefit independent of PD-L1 expression; published in Cancer Cell 2022. NMPA approval May 2022. One of five Chinese PD-1 trials (with ESCORT-1st, ORIENT-15, RATIONALE-306 and KEYNOTE-590) that made chemo-immunotherapy the first-line standard in a cancer where China has about half the world's cases.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-10
- Tags: china
- Registry id: NCT03829969
- Phase: 3
- Setting: First-line advanced oesophageal squamous cell carcinoma, China: toripalimab or placebo plus paclitaxel and cisplatin
- Sponsor: Shanghai Junshi Biosciences
- Enrolled: 514
- Result: OS 17.0 vs 11.0 months (HR 0.58); PFS HR 0.58.
- Outcomes: Overall survival: Toripalimab + TP 17 months vs Placebo + TP 11 months, HR 0.58

## Sources

- ClinicalTrials.gov NCT03829969: https://clinicaltrials.gov/study/NCT03829969
- Cancer Cell 2022: https://doi.org/10.1016/j.ccell.2022.02.007

## Connected records

- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [Shanghai Junshi Biosciences](https://onco.cc/companies/junshi/)
- people: [Rui-Hua Xu](https://onco.cc/people/xu-rui-hua/)
- key papers: [Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial](https://onco.cc/key-papers/paper-wang-cancer-cell/)

---
JSON: https://onco.cc/api/v1/entities/jupiter-06.json